ReviewInternational journal of molecular sciences2013
The genomic landscape of prostate cancer.
Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Molecular Landscape of Prostate Cancer Across Age Groups: Impact on Prognosis and Treatment Outcomes.International journal of molecular sciences · 2025Review
- Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer.Frontiers in oncology · 2022Article
- Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.Nature reviews. Urology · 2021Review
- Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.Cells · 2020Review
- Mapping the Germline and Somatic Mutation Interaction Landscape in Indolent and Aggressive Prostate Cancers.Journal of oncology · 2019Article
- Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.Genome biology · 2017Article
- Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.Current genomics · 2017Review
- Article
- Molecular Mechanism ofJournal of pharmaceutical sciences and pharmacology · 2015Article
- Evaluation of hGM-CSF/hTNFα surface-modified prostate cancer therapeutic vaccine in the huPBL-SCID chimeric mouse model.Journal of hematology & oncology · 2015Article
- CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cells.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.Genome biology · 2014Article
- Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.Nature reviews. Cancer · 2014Review
- Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.PloS one · 2014Article
- Evolving Personalized Therapy for Castration-Resistant Prostate Cancer.BioMedicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By the age of 80, approximately 80% of men will manifest some cancerous cells within their prostate, indicating that prostate cancer constitutes a major health burden. While this disease is clinically insignificant in most men, it can become lethal in others. The most challenging task for clinicians is developing a patient-tailored treatment in the knowledge that this disease is highly heterogeneous and that relatively little adequate prognostic tools are available to distinguish aggressive from indolent disease. Next-generation sequencing allows a description of the cancer at an unprecedented level of detail and at different levels, going from whole genome or exome sequencing to transcriptome analysis and methylation-specific immunoprecipitation, followed by sequencing. Integration of all these data is leading to a better understanding of the initiation, progression and metastatic processes of prostate cancer. Ultimately, these insights will result in a better and more personalized treatment of patients suffering from prostate cancer. The present review summarizes current knowledge on copy number changes, gene fusions, single nucleotide mutations and polymorphisms, methylation, microRNAs and long non-coding RNAs obtained from high-throughput studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.